Key takeaways:
1. Overview of burden of disease for respiratory syncytial virus (RSV)
2. Review of the ACIP Meeting June 21, 2023 Recommendations for RSV Vaccines and subsequent MMWR Publication July 21, 2023.
3. Review bivalent RSV Prefusion F Vaccine (RSVpreF), including safety and efficacy in adults 60 years of age and older.